Nephron Research upgraded West Pharmaceutical (WST) to Buy from Hold with a $367 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical initiated with an Equal Weight at Morgan Stanley
- West Pharmaceutical initiated with a Buy at TD Cowen
- West Pharmaceutical removed from ‘Tactical Outperform’ list at Evercore ISI
- West Pharmaceutical price target raised to $325 from $275 at Barclays
- West Pharmaceutical price target raised to $370 from $310 at BofA